Objective An ambitious long-term programme of multidisciplinary research with two closely linked objectives is proposed to support antimicrobial drug development. Firstly, to advance understanding, at the molecular level, of fundamental and important aspects of the biology of Gram-negative bacteria using the important pathogen model Pseudomonas aeruginosa. Secondly, and most important, to exploit our discoveries and develop ligands and inhibitors (hit and lead compounds) with the potential to underpin the discovery of improved therapies for Gram-negative infections. The research covers five distinct areas, or work packages. (WPI) The experimental validation and therefore identification of novel targets by gene knockout in P. aeruginosa. (WPII) Cloning, characterisation, biochemical and structural biology, of the novel targets. (WPIII) A directed, search for ligands/inhibitors, exploiting data from WPI and WPII, for these validated antimicrobial drug targets by virtual screening (VS) and assessment of druggabilty, high-throughput screening (HTS) of a carefully prioritised subset of targets. (WPIV) The characterisation of the interactions formed between the drug target and the ligand/inhibitor by biochemical and crystallographic study, computational modelling and then design and modelling to enhance binding properties. (WPV) The initial biological testing for efficacy against Gram-negative bacteria. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverynatural sciencesbiological sciencesmicrobiologybacteriologynatural sciencesbiological sciencesmolecular biologystructural biology Keywords antimicrobial crystallography drug targets pseudomonas screening structural biology Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Topic(s) HEALTH-2007-2.3.1-1 - Novel targets for drugs against Gram negative bacteria Call for proposal FP7-HEALTH-2007-B See other projects for this call Funding Scheme CP-FP - Small or medium-scale focused research project Coordinator UNIVERSITY OF DUNDEE EU contribution € 1 545 279,00 Address Nethergate DD1 4HN Dundee United Kingdom See on map Region Scotland Eastern Scotland Angus and Dundee City Activity type Higher or Secondary Education Establishments Administrative Contact Zoe Kidd (Ms.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data Participants (4) Sort alphabetically Sort by EU Contribution Expand all Collapse all LIONEX GMBH Germany EU contribution € 639 003,00 Address Salzdahlumer Strasse 196 38126 Braunschweig See on map Region Niedersachsen Braunschweig Braunschweig, Kreisfreie Stadt Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Mahavir Singh (Prof.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data KAROLINSKA INSTITUTET Sweden EU contribution € 887 614,00 Address Nobels Vag 5 17177 Stockholm See on map Region Östra Sverige Stockholm Stockholms län Activity type Higher or Secondary Education Establishments Administrative Contact Jill Blomstrand (Ms.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS United Kingdom EU contribution € 1 064 967,00 Address NORTH STREET 66 COLLEGE GATE KY16 9AJ St Andrews See on map Region Scotland Eastern Scotland Clackmannanshire and Fife Activity type Higher or Secondary Education Establishments Administrative Contact Fiona Thomson (Ms.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data Mfd-diagnostics GmbH Germany EU contribution € 454 600,00 Address Mikroforum Ring 2 55234 Wendelsheim See on map Region Rheinland-Pfalz Rheinhessen-Pfalz Alzey-Worms Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Bernd Lecher (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data
